Neuroscience
A newly developed, more specific approach to classifying tumors by molecular type can help cancer researchers to determine tumor characteristics and guide treatment strategies.
A team of researchers from the Perelman School of Medicine at the University of Pennsylvania and the Wistar Institute have created the first isoform-level assay for stratifying tumors at a molecular level, in patients with glioblastoma, the most common and most aggressive type of malignant primary brain tumor. This new classifier is more efficient and replicable in a laboratory setting than existing diagnostic tools, and can provide more accurate predictions for survival and how glioblastoma patients may respond to different treatments.
"Current tests can help classify tumor types to a lesser degree. This new classifying system improves both the diagnostic accuracy and the efficiency of the testing process," said Donald O'Rourke, MD, associate professor of Neurosurgery with Penn's Abramson Cancer Center and director of the Penn Brain Tumor Tissue Bank. "The more detailed information we have about the tumor, at a molecular level, the better we can target new immunotherapies and other treatments for our patients with glioblastoma."
Read the full article.
- Penn Proud To Serve As Flagship Sponsor For Race For Hope
Now entering its 10th year, the National Brain Tumor Society's Race for Hope is a 5K Run/Walk fundraiser to support the brain tumor community. The Race for Hope is a way to reach other families, patients and survivors affected by brain tumors. Penn...
- Personalized T Cell Therapy Shows Promise In Stopping Brain Tumor Growth
A recent study, published in Science Translational Medicine, suggests hope for glioblastoma patients. The approach, which included members from the Perelman School of Medicine at the University of Pennsylvania and the Novartis Institutes for BioMedical...
- Dr. O'rourke Discusses Aggressive Treatment Facing Darren Daulton
Donald O'Rourke, MDPenn Medicine neurosurgeon Donald O'Rourke, MD, was interviewed by Comcast SportsNet and 6ABC discussing the outlook for former Phillies player Darren Daulton, who was diagnosed with the brain cancer glioblastoma following surgery...
- Improving Treatment For Brain Cancer Patients
Steven Brem, MDThe American Society of Clinical Oncology (ASCO) features an interview with Steven Brem, MD in its June issue of The ASCO POST. Dr. Brem, Co-Director of the Penn Brain Tumor Center and Professor of Neurosurgery, talks about the current...
- Steven Brem, Md Receives American Brain Tumor Association Award
Steven Brem, MD, Professor of Neurosurgery, Chief of the Division of Neurosurgical Oncology and Co-Director of the Penn Brain Tumor Center, has received the first Joel A. Gingras, Jr. award given by the American Brain Tumor Association (ABTA). Dr. Brem...
Neuroscience
Penn Neurosurgery Creates Precise Tumor Classifier for Glioblastoma
A newly developed, more specific approach to classifying tumors by molecular type can help cancer researchers to determine tumor characteristics and guide treatment strategies.
 |
| Donald O'Rourke, MD |
A team of researchers from the Perelman School of Medicine at the University of Pennsylvania and the Wistar Institute have created the first isoform-level assay for stratifying tumors at a molecular level, in patients with glioblastoma, the most common and most aggressive type of malignant primary brain tumor. This new classifier is more efficient and replicable in a laboratory setting than existing diagnostic tools, and can provide more accurate predictions for survival and how glioblastoma patients may respond to different treatments.
"Current tests can help classify tumor types to a lesser degree. This new classifying system improves both the diagnostic accuracy and the efficiency of the testing process," said Donald O'Rourke, MD, associate professor of Neurosurgery with Penn's Abramson Cancer Center and director of the Penn Brain Tumor Tissue Bank. "The more detailed information we have about the tumor, at a molecular level, the better we can target new immunotherapies and other treatments for our patients with glioblastoma."
Read the full article.
Penn Neurosurgery provides comprehensive surgical management of disorders of the brain, spinal cord and peripheral nervous system.
Learn more about Penn Neurosurgery.
Learn more about Penn Neurosurgery.
- Penn Proud To Serve As Flagship Sponsor For Race For Hope
Now entering its 10th year, the National Brain Tumor Society's Race for Hope is a 5K Run/Walk fundraiser to support the brain tumor community. The Race for Hope is a way to reach other families, patients and survivors affected by brain tumors. Penn...
- Personalized T Cell Therapy Shows Promise In Stopping Brain Tumor Growth
A recent study, published in Science Translational Medicine, suggests hope for glioblastoma patients. The approach, which included members from the Perelman School of Medicine at the University of Pennsylvania and the Novartis Institutes for BioMedical...
- Dr. O'rourke Discusses Aggressive Treatment Facing Darren Daulton
Donald O'Rourke, MDPenn Medicine neurosurgeon Donald O'Rourke, MD, was interviewed by Comcast SportsNet and 6ABC discussing the outlook for former Phillies player Darren Daulton, who was diagnosed with the brain cancer glioblastoma following surgery...
- Improving Treatment For Brain Cancer Patients
Steven Brem, MDThe American Society of Clinical Oncology (ASCO) features an interview with Steven Brem, MD in its June issue of The ASCO POST. Dr. Brem, Co-Director of the Penn Brain Tumor Center and Professor of Neurosurgery, talks about the current...
- Steven Brem, Md Receives American Brain Tumor Association Award
Steven Brem, MD, Professor of Neurosurgery, Chief of the Division of Neurosurgical Oncology and Co-Director of the Penn Brain Tumor Center, has received the first Joel A. Gingras, Jr. award given by the American Brain Tumor Association (ABTA). Dr. Brem...